Treatment of Atopic Dermatitis.
- Author:
Tae Young HAN
1
;
Chan Ho NA
;
Ji Hyun LEE
;
Hye One KIM
;
Chang Ook PARK
;
Young Joon SEO
;
Sang Wook SON
;
Min Kyung SHIN
;
Ji Young AHN
;
Yang Won LEE
;
Yong Hyun JANG
;
Young Lip PARK
;
Bark Lynn LEW
Author Information
1. Department of Dermatology, College of Medicine, Eulji University, Daejeon, Korea.
- Publication Type:Review Article
- Keywords:
Atopic dermatitis;
Guideline;
Treatment
- MeSH:
Adrenal Cortex Hormones;
Adult;
Anti-Bacterial Agents;
Calcineurin Inhibitors;
Child;
Cyclosporine;
Dermatitis, Atopic*;
Humans;
Immunosuppressive Agents;
Phototherapy;
Pruritus;
Quality of Life;
Skin Diseases;
Steroids;
United States Food and Drug Administration
- From:Korean Journal of Dermatology
2018;56(10):581-593
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects both children and adults. AD is the cause of considerable morbidity including severe pruritus and impaired quality of life. Treatments for active disease include avoidance of triggering factors, barrier repair, topical medications including topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs), phototherapy, antibacterial agents, and systemic immunosuppressants including cyclosporine. Until recently, the only Food and Drug Administration (FDA)-approved systemic treatment options for patients with moderate-to-severe AD were steroids and cyclosporine. Systemic steroids are not recommended by current guidelines and are commonly associated with disease rebound. Instead, clinicians choose from several off-label immunosuppressants. In 2018, the Korean FDA approved dupilumab for adults with moderate-to-severe AD whose disease is not adequately controlled with topical therapies. The implementation of treatment guidelines for AD is challenging. Herein, we review the several treatment modalities for AD and recommend a treatment algorithm.
